@onclive.bsky.social
@lungcancereurope.bsky.socialA rare inherited EGFR variant has been linked to around 25× higher odds of #LungCancer.
- genetic data from 3.3M+
- could inform future genetic testing & screening
How do we make sure evidence like this leads to earlier detection & fair access to screening? hms.harvard.edu/news/rare-in... #LCSM
@oncogenecancer.bsky.socialFour sisters. Always close. Amy was just 20 when she was diagnosed with stage 4 ALK+ lung cancer.
On 11 October, her sister Gemma runs the Bournemouth Half Marathon to fund research—and hope for more time together. 🩵
Support Gemma: www.kindlink.com/fundraising/...
@lungcancereurope.bsky.socialIn an I3LUNG study of 2,396 people with advanced #lungcancer, an AI model using routine data predicted 24-month survival better than PD-L1 alone. Performance fell at another centre, so it needs more testing.
New research in Nature Medicine: www.nature.com/articles/s41... #LCSM
@lungcancereurope.bsky.socialThe EU Biotech Act is moving through the European Parliament.
For #lungcancer, key issues include biomarker testing, cross-border trials, patient involvement and access to innovation across Europe.
@onclive.bsky.social🗞️ A @fda.gov NDA submission has been initiated for zipalertinib plus platinum-based chemotherapy in frontline, EGFR exon 20 insertion–positive NSCLC #lcsm #oncology
Dive into the REZILIENT3 data supporting the application: www.onclive.com/view/nda-sub...
@onclive.bsky.social
@btog.bsky.socialFunding competition: Innovate UK invests £25.4M to advance early cancer diagnosis. Apply by 28 Oct 2026! https://ow.ly/TeNx50ZCn3G #LCSM #LungCancer
@onclive.bsky.social📰 The @fda.gov granted fast track designation to plinabulin plus docetaxel for advanced or metastatic nonsquamous NSCLC without actionable genomic alterations after progression on prior therapy. #lcsm #oncology
Full story ➡️: www.onclive.com/view/fda-gra...
@lungcancereurope.bsky.socialThe link between #lungcancer and heart health runs both ways. The conditions share risks, and some lung cancer treatments can affect the heart.
More on the evidence and what it means for care this #WorldHeartDay: lungcancereurope.eu/news/lung-ca... #LCSM
@eaonc.bsky.social#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: AI Support in Clinical Decision Making presented by Arsela Prelaj. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@btog.bsky.social📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
@lungcancereurope.bsky.socialPeople with #LungCancer should not have to coordinate every part of their care themselves.
Today at #WCC2026, our VP presented collab work with LCPN on patient navigation: practical support to help people move between services and get the care they need.
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: AI in Pathological Diagnosis of Lung Cancer presented by Mehrdad Rakaee. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@lungcancereurope.bsky.socialIn a small trial in Turkey, 84 people newly diagnosed with non-small cell #LungCancer were assigned to a 12-wk nurse navigation programme or usual care.
The navigation group reported less depression & stress, & better QOL + fewer emergency department visits. #LCSM
@onclive.bsky.socialWATCH 📺: In this episode of #OncLiveOnAir 🎙️, Narjust Florez, MD, of @danafarber.bsky.social, and Jonathan Wesley Riess, MD, MS, of @ucdavis.bsky.social, discuss HER2 overexpression vs HER2 mutations in NSCLC. #lcsm #oncology
Watch or listen ➡️: www.onclive.com/view/recent-...
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: Enhancing Radiology Through AI presented by Rebecca Wray. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@lungcancereurope.bsky.social#LungCancer surgery became more common in England.
Among 308,000+ people with NSCLC, the proportion having surgery rose from 15.4% (2015) to 20.9% (2023).
Stage I diagnoses rose from 17.4% to 26.8%.
Early diagnosis must lead to timely treatment.
@lungcancereurope.bsky.socialEarlier #lungcancer testing found no target. Broader genomic profiling found a driver alteration in 37%.
🆕 Japanese study inclu 2,296 people with advanced or recurrent #NSCLC.
For Europe we need the right test, early enough, followed by trtmt that matches the result.
